Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!
Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!

Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over the counter medications.

Siddharth Mane Article rating: 4.7

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR